Skip to content
Loading...
Search for:
Search
About
Management
Board of Directors
Advisory Board
History
Governance
General Meetings
Governance reports
Board Committees
Nomination Committee
Articles of Association
Auditor
Code of Conduct
Career
Our Science
Focus Areas
Autoimmune and Inflammatory Diseases
Host-Directed Therapy – Viral Infections
Our Medicines
Oral Drugs
Peptides
Synact Wiki
Diseases
Rheumatoid Arthritis
Nephrotic Syndrome
Polymyalgia Rheumatica
Dengue Fever
COVID-19
Development Program
Resomelagon
Inflammatory and Autoimmune Diseases
RA: The BEGIN Study
RA: The EXPAND Study
RA: The RESOLVE Study
RA: The ADVANCE Study
iMN: SynAct-CS003
Host-Directed Therapy in Viral Infections
COVID-19: RESOVIR-1
Dengue Fever: RESOVIR-2
Respiratory viral infections: RESPIRE
TXP-11
Scientific Publications
Resolution Therapy
Resomelagon (AP-1189) in Rheumatoid Arthritis
Resomelagon (AP-1189) in Viral Infections
Investors
Message from the CEO
Investment Highlights
Financial Reports
The Share
Share capital
Ownership Structure
Board and Management Holdings
Analysts
Presentations
Calendar
Prospectus and Rights Issues
News & Media
News and Press Releases
SynAct in the Media
Slide Decks and Presentations
Image Bank
ENG
SVE
Search
Search for:
Search
The Share
Loading...
Loading...
Loading...
Volume
Loading...
